Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Dose-escalation Study of MDX-010 Administered Every 3 Weeks for 4 Doses in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00323882 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00323882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00323882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Dose-escalation Study of MDX-010 Administered Every 3 Weeks for 4 Doses in Patients With Metastatic Hormone-Refractory Prostate Cancer
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2006
Completion date
July 31, 2013
Enrollment
75 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, prostate cancer